C hronic pathologic stress to the heart results in structural and functional remodeling, accompanied by various molecular and cellular changes, including myocyte hypertrophy, inflammatory and fibrogenic responses, and myocyte death which often culminate in heart failure (HF) and sudden death (1, 2) . Clinical studies have shown that patients suffering from HF are at risk of sustaining thromboembolic events partly due to increased activity of pro-coagulant factors and increased platelet activation (3, 4) . Although the primary function of the coagulation cascade is to promote hemostasis and limit blood loss in response to tissue injury, it is now recognized that the physiologic functions of the coagulation factors extend beyond blood coagulation and that these factors play pivotal roles in influencing processes such as angiogenesis, inflammation, and repair in response to tissue injury (5) . Therefore, targeting these factors may provide a mean by which to improve the outcome of HF therapies. Activated coagulation factor X (FXa) is a serine protease that plays a central role in the coagulation cascade (6) , which, during hemostasis, forms a prothrombinase complex with factor Va on a phospholipid membrane surface, leading to thrombin generation (6) . Treatment strategies directly targeting FXa have been established for atrial fibrillation (7) , deep vein thrombosis (8) , and pulmonary embolism (9) .
Recently, lower doses of rivaroxaban (e.g., 2.5 mg twice daily) in combination with antiplatelet agents have been found to reduce the risk of death from cardiovascular causes, myocardial infarction, and stroke in patients with acute coronary syndromes or stable coronary artery disease (10, 11) . Moreover, analysis of a subgroup of patients with a history of HF who were enrolled in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial suggested that they may benefit from treatment with rivaroxaban in combination with aspirin (12) . Recent evidence shows that FXa may exert its effects on other systems beyond blood coagulation (5) . Such nonhematologic functions of FXa actions could be mediated through protease-activated receptor (PAR)1 and/or PAR-2 cleavage, which depend on the receptorspecific cell expression pattern, ligand concentration, solubility, or association with other coagulation factors (5) . The proteolytic cleavage of PAR-1 and PAR-2 by FXa results in the activation of a canonical G-protein pathway and, consequently, of downstream signaling pathways that trigger multiple transcriptionregulated, cell-specific events. In the heart, PAR-1 and PAR-2 are each expressed in several cardiac cells, including myocytes and fibroblasts, with expression increased in response to cardiac injury or stress (13) . Genetic and pharmacologic investigations showed the involvement of PAR-1 and PAR-2 on adverse cardiac remodeling and function in response to various stressors (13) (14) (15) (16) . Whether the beneficial effects of FXa inhibition by rivaroxaban are mediated through its actions on blood coagulation, cardiac cells, or both are not well understood.
Factor X (FX) is synthesized in the liver and is locally activated in response to tissue injury as a result of vascular leak and extravascular tissue-factor expression. However, it is unknown whether FXa can be derived from a local cardiac source rather than from the circulation, which may represent an additional extravascular mechanism for the generation of FXa. In the present study, we investigated whether local expression of FX is increased in heart after transverse aortic constriction (TAC) to induce pressure overload (PO) and the mechanisms by which FXa affects cardiac myocyte and fibroblast growth. We also studied the pharmacokinetic of FXa inhibition by rivaroxaban to determine whether a non-anticoagulation dosage of rivaroxaban is effective in reducing adverse cardiac remodeling and function in mice subjected to TAC independently of its effect of blood coagulation. We provide new insights into our understanding of the cellular origin of excessive coagulation activity in heart following PO-induced stress and we propose that FXa, derived from a local cardiac source rather than from the circulation, may represent an important physiologic and pathophysiologic activator of PAR-1/ PAR-2 in extravascular compartments in the absence of hematoma and microvascular leak. (19) and are locally activated in response to tissue injury as a result of vascular leak.
METHODS
However, some studies have proposed an additional mechanism for the generation of FXa via local extravascular expression of FX (20, 21) . We investigated whether FX is locally produced in the murine heart after TAC by real-time quantitative polymerase chain reaction. Figure 1A We next investigated the expression of intrinsic and extrinsic coagulation factors that activate FX given FX mRNA is increased in cardiac myocytes and fibroblasts. Supplemental Figures S1B, S1C, S1E, and S1F show increased FIII, but not FVIII, mRNA expression in response to FXa and thrombin in cardiac myocytes and fibroblasts. Increased FIII mRNA expression was also observed in cardiac myocytes and fibroblasts treated with phenylephrine or transforming growth factor (TGF)-b, which were taken as positive controls for cardiomyocyte hypertrophy and fibroblast differentiation, respectively. These data imply that coagulation FX is produced in cardiac myocytes and fibroblasts, which in turn can mediate cardiac hypertrophy and fibrosis. We next evaluated the role of FXa in the sequelae of PO stress beyond its effect on blood coagulation.
C57BL6 mice were administered vehicle or nonanticoagulation dosage of rivaroxaban (1 mg/kg/d,
FIGURE 2 Effect of Rivaroxaban on Thrombin Generation and Blood Coagulation
Mice were treated without or with rivaroxaban at 1 and 10 mg/kg (intraperitoneal injection) and then sacrificed at 0, 2, and 4 h after injection. Platelet poor plasma was assayed for rivaroxaban activity assay (using anti-FXa activity assay) (A), thrombin generation assay (TGA) using calibrated automated thrombogram (B-F), activated partial thromboplastin time (aPTT) (G), or prothrombin time (PT) (H). Note that blood circulating rivaroxaban levels were increased in mice treated with 1 mg/kg rivaroxaban at 2 and 4 h after injection (A), but show no changes in TGA kinetics (B), endogenous thrombin potential (ETP) (C), thrombin peak height (D), lag time (E), thrombin generation time to peak (F), aPTT (G), or PT (H) compared to vehicle-treated mice. In contrast, mice treated with 10 mg/kg rivaroxaban show significant changes in all these parameters described above (n ¼ $ 3 to 4 for each group). *p < 0.05 versus untreated mice. Riv ¼ rivaroxaban; other abbreviation as in Figure 1 . Table S1 ). Figure S7 ).
Post
Collectively, these data implicate FXa as a positive regulator of cardiac hypertrophic signaling.
We next determined whether FXa signaling is mediated through stimulation of PAR-1 and/or PAR-2, 2 receptors that have been shown to mediate FXa actions in other cell types (25) . Figure 5D shows that Results are expressed as RFU/min/mg protein (n ¼ 5 for each group). Values are presented as mean AE SEM, *p < 0.05 vs. shams, †p < 0.05 vs. vehicle-treated TAC.
Col. III ¼ collagen type III; CTGF ¼ connective tissue growth factor; MMP ¼ matrix metalloprotease; TGF ¼ transforming growth factor; TIMP ¼ tissue inhibitor of metalloprotease; other abbreviations as in Figures 1 and 2 .
Guo et al. Figure S11B ). We also determined whether fibroblast migration and proliferation are sensitive to rivaroxaban. Figure 7B Some studies challenged the concept that coagulation zymogens FXa are synthesized in the liver, travel through the blood and entering tissues where they are locally activated in response to injury (20, 21) .
Our new findings propose an additional mechanism for cardiac FXa activity, via local expression of FX in the heart. FX mRNA expression was increased in the stressed myocardium with prominent sites of FX/FXa immunoreactivity detected in interstitial space of cardiac fibrosis and surrounding cardiomyocytes after TAC. We further showed that neurohormonal stressors were capable of substantially upregulating FX mRNA levels in isolated cardiac myocytes and fibroblasts in vitro, with cardiac fibroblasts expressing higher levels of FX than isolated cardiac myocytes.
Because of their abundance in the heart, we suspect that cardiac fibroblasts may be a major contributor of the total FX expression in the heart precisely when Our finding that MMP2/9 activity was reduced in rivaroxaban-treated TAC hearts suggests that rivaroxaban can modulate thrombin receptor signaling through this mechanism. 
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